Form 4: Vaxcyte Director John Furey Acquires 16,760 Stock Options

Director John Furey acquired 16,760 stock options in Vaxcyte, Inc. on July 2, 2024.

Summary

• On July 2, 2024, John Furey, a director of Vaxcyte, Inc. (PCVX), acquired 16,760 stock options.
• The exercise price of these options is $76.06.
• The options vest over 36 months, with 1/3 vesting on July 2, 2025, and the remainder vesting monthly thereafter, contingent upon continuous service to the company.
• The expiration date for these options is July 1, 2034.
• Following the transaction, Furey directly owns 16,760 derivative securities.

Sentiment

Score: 7

Explanation: The acquisition of stock options by a director is generally viewed positively as it aligns their interests with shareholders. The vesting schedule suggests a long-term commitment.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting schedule indicates a long-term incentive for the director to remain with the company and contribute to its success.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Stakeholder Impact

• The acquisition of stock options by a director can positively influence shareholder sentiment.

Key Dates